Skip to main content
. Author manuscript; available in PMC: 2018 Sep 21.
Published in final edited form as: Cell Chem Biol. 2017 Sep 21;24(9):1075–1091. doi: 10.1016/j.chembiol.2017.08.002

Table 1.

Advances in Chordoma Research Assets

2007 2017 Interventions
Researcher community Small, disconnected >300 active researchers; robust collaboration International Chordoma Research Workshops; networking events
Patient community None >1,800 patients Facebook group; website; online advertising and search engine optimization; educational materials; Chordoma Community Conferences
Tumor tissue Scarce, no centralized source Centralized repository with tissue from >200 cases Tumor donation program allows patients to donate tumor from any US hospital; CF Biobank stores and distributes tumor samples
Genome characterization None 35 cases sequenced Chordoma Genome Project, in partnership with academic labs
Cell lines 1 17 Cell line prize; cell line validation pipeline; genomic characterization; publicly accessible cell-line repository
Patient-derived xenografts (PDX) None 5 Tumor donation program coupled with rapid implantation in vivo; PDX prize; PDX validation pipeline; publicly accessible PDX repository
Small-molecule screening None >10,000 compounds screened, including all FDA-approved drugs Collaboration with NIH Chemical Genomics Center; grants to academic investigators; collaborations with industry
Functional genomic screening None Genome-wide CRISPR/Cas9 screens; targeted shRNA screen Grants to academic investigators
In vivo evaluation None >20 drugs evaluated CF drug screening pipeline provides in vivo evaluation as a service to academic and industry collaborators
Clinical trials 1 completed clinical trial Pipeline of 7 new clinical trials Clinical trials program supports trials with: funding, trial design, patient education, and outreach

Source material: Chordoma Foundation (J. Sommer, personal communication) and www.chordomafoundation.org.